EUVIMEDEUVIMED entdecken
Leitlinie

Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments

Aaron P Mitchell iD, Aaron N Winn, Patrick Augello iD, Grace Gallagher iD, Akriti Mishra Meza iD, Abdullah Abdelaziz iD, Gabrielle Guzman iD, Nina Galanter iD, Nirjhar Chakraborty iD, Maria Klimchuk iD, Susan Alsamarai, S Vincent Rajkumar iD und 3 weitere

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3105-3115

DOI: 10.1200/jco-26-00785 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Aaron P Mitchell und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Drug Industry, Oncologists, Neoplasms, Practice Patterns, Physicians'. Die Arbeit nennt 60 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Payments from the drug industry influence physicians' prescribing decisions. Whether industry payments affect the likelihood that patients receive the guideline-preferred treatment for their cancer is unknown. METHODS We used fee-for-service Medicare claims to identify patients with an incident cancer diagnosis from 2014 to 2020. We used the National Comprehensive Cancer Network (NCCN) guidelines to identify cancers with variation in clinical benefit among recommended treatment options and to identify the preferred treatment as of each patient's diagnosis date. The primary exposure was drug industry payments received by the patient's medical oncologist during the year before diagnosis, categorized as no payment, payment for preferred treatment only, payment for nonpreferred treatment only, or payment for both. The primary outcome was receipt of a preferred treatment. RESULTS There were 14 cancer scenarios comprising 15,607 patients; 60.2% were managed by oncologists who received no payment, 21.9% by oncologists who received payment for guideline-preferred treatment, 30.6% by oncologists who received payment for nonpreferred treatment, and 12.7% by oncologists who received both payment types. Among patients whose oncologist received no payments, 41.6% received payments for preferred treatment versus 51.5% of those whose oncologist received payments for guideline-preferred treatment only, 34.7% of those whose oncologist received payments for nonpreferred treatment only, and 42.9% of those whose oncologist received payments for both payment types. After adjustment, payment for guideline-preferred treatment was associated with a greater likelihood of receiving preferred treatment (risk ratio [RR] = 1.06 [95% CI, 1.01 to 1.13]) and payment for nonpreferred treatment was associated with a lower likelihood (RR, 0.93 [95% CI, 0.89 to 0.98]). Association magnitude increased as payment dollar value increased. CONCLUSION Industry payments were associated with increased use of the promoted cancer treatment, regardless of whether that treatment was guideline-preferred or nonpreferred for a given patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryOncologistsNeoplasmsPractice Patterns, Physicians'HumansUnited StatesFemaleMaleMedicareConflict of InterestAgedPractice Guidelines as TopicAged, 80 and overFee-for-Service Plans

Autor:innen und Institutionen

  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • University of Illinois Chicago, Chicago, IL.
  • Department of Finance, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Hartford HealthCare, MidState Medical Center, Meriden, CT.
  • Division of Hematology, Mayo Clinic, Rochester, MN.

ORCID-Profile: Aaron P Mitchell, Patrick Augello, Grace Gallagher, Akriti Mishra Meza, Abdullah Abdelaziz, Gabrielle Guzman, Nina Galanter, Nirjhar Chakraborty, Maria Klimchuk, S Vincent Rajkumar, Peter B Bach, Mithat Gönen, Stacie B Dusetzina

Förderung

  • NCI NIH HHS

Zitieren

APA

Mitchell, A. P., Winn, A. N., Augello, P., Gallagher, G., Mishra Meza, A., Abdelaziz, A., Guzman, G., Galanter, N., Chakraborty, N., Klimchuk, M., Alsamarai, S., Rajkumar, S. V., Bach, P. B., Gönen, M., & Dusetzina, S. B. (2026). Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments. Journal of Clinical Oncology, 44(32), 3105-3115. https://doi.org/10.1200/jco-26-00785

Vancouver

Mitchell AP, Winn AN, Augello P, Gallagher G, Mishra Meza A, Abdelaziz A, et al. Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments. Journal of Clinical Oncology. 2026;44(32):3105-3115. doi:10.1200/jco-26-00785

BibTeX
@article{Mitchell2026,
  author = {Mitchell, Aaron P and Winn, Aaron N and Augello, Patrick and Gallagher, Grace and Mishra Meza, Akriti and Abdelaziz, Abdullah and Guzman, Gabrielle and Galanter, Nina and Chakraborty, Nirjhar and Klimchuk, Maria and Alsamarai, Susan and Rajkumar, S Vincent and Bach, Peter B and Gönen, Mithat and Dusetzina, Stacie B},
  title = {Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3105--3115},
  doi = {10.1200/jco-26-00785}
}
Kostenlos starten →